Lipoprotein(a) as a Causal Cardiovascular Risk Factor: Pathobiology, Risk Stratification, and Emerging Therapeutics

Key Takeaways

• Lipoprotein(a) is a genetically determined causal driver of atherosclerotic cardiovascular disease and calcific aortic stenosis. Approximately one in five adults has elevated concentrations that a standard lipid panel fails to capture. No therapy that specifically lowers Lp(a) has yet been shown to reduce cardiovascular events; precisely herein lies the central clinical dilemma.
• Pathogenicity stems from apolipoprotein(a), a glycoprotein disulfide-linked to apoB-100 and homologous to plasminogen. Kringle IV type 2 copy number determines both isoform size and plasma concentration; its oxidized phospholipid cargo confers proinflammatory, osteogenic, and antifibrinolytic activity that extends well beyond the particle’s cholesterol payload.
• Lp(a) should be measured at least once in every adult, preferably using an isoform-insensitive assay reporting in nmol/L. Values below 75 nmol/L (approximately 30 mg/dL) are generally reassuring. Levels of 105 to 125 nmol/L (approximately 50 mg/dL) and above represent a risk-enhancing factor; concentrations exceeding 180 mg/dL (approximately 430 nmol/L) confer a cardiovascular risk burden equivalent to heterozygous familial hypercholesterolemia.
• Pending the readouts of clinical outcome trials, clinical management centers on intensive LDL-C and apoB lowering calibrated to the patient’s global cardiovascular risk. In secondary prevention and high-risk primary prevention, this strategy targets high-intensity statins, early ezetimibe, and PCSK9 inhibition in selected cases. It also encompasses stringent control of blood pressure, blood glucose, and tobacco use, coronary artery calcium scoring in primary prevention, and cascade screening of first-degree relatives.
• Antisense oligonucleotides and siRNA agents (pelacarsen, olpasiran, lepodisiran, zerlasiran) reduce Lp(a) levels by 80% to more than 95% and have been well tolerated in early-phase trials. Statins may modestly increase Lp(a); however, this should never serve as a rationale to withhold statin therapy. Niacin is not recommended. Low-dose aspirin and lipoprotein apheresis should be reserved for carefully selected phenotypes.

Introduction and Clinical Background

Lipoprotein(a) [Lp(a)] occupies a paradoxical and challenging position in contemporary cardiovascular medicine. The evidence demonstrating that it drives atherosclerosis and aortic valve disease is stronger than that for nearly any lipid fraction other than LDL cholesterol. Yet, until now, clinicians have lacked any therapeutic option that specifically lowers Lp(a) and demonstrates proven clinical outcome benefit. Elevated Lp(a) levels are present in approximately one in five individuals worldwide; the particle’s enrichment in oxidized phospholipids confers proinflammatory, prothrombotic, and proatherogenic properties that perpetuate residual risk despite optimal control of traditional risk factors^[1]. Accordingly, Lp(a) has emerged as a promising novel therapeutic target in both atherosclerotic cardiovascular disease and aortic stenosis^[2].

The causality hypothesis rests on concordant lines of evidence. Prospective epidemiological data demonstrate a continuous and generally linear relationship between Lp(a) concentration and atherosclerotic cardiovascular disease (ASCVD) risk when reliable measurement methods are employed. Subsequent Mendelian randomization studies corroborated this causal link by showing that genetically determined Lp(a) levels track directly with coronary and valvular outcomes^[3]. The same body of evidence also revealed that existing LDL-lowering therapies exert minimal or no effect on Lp(a). This establishes Lp(a) not as a surrogate for LDL burden, but as an independent axis of residual risk. Across observational and genetic datasets, elevated Lp(a) is associated with coronary heart disease, myocardial infarction, ischemic stroke, peripheral artery disease, and calcific aortic valve stenosis. The consensus cutoff defining elevated levels is approximately 125 nmol/L or 50 mg/dL^[4].

Recent real-world evidence confirms the practical manifestations of this disease burden. In a retrospective Polish cohort of 23,654 adults whose levels were measured in nmol/L, the median Lp(a) concentration was 12.7 nmol/L (interquartile range [IQR], 7.0 to 47.0). Log-transformed Lp(a) was independently associated with ASCVD (OR 1.15; 95% CI, 1.07 to 1.24), coronary artery disease (OR 1.21; 95% CI, 1.12 to 1.32), and prior myocardial infarction (OR 1.78; 95% CI, 1.31 to 2.41), but not with stroke or transient ischemic attack (TIA) (OR 0.97; 95% CI, 0.86 to 1.09). This independent association remained robust for ASCVD and coronary artery disease even in the subgroup of patients with LDL-C levels below 70 mg/dL^[5]. The persistence of risk even at low LDL-C concentrations underscores a critically important clinical point: a patient at goal LDL levels may still harbor unmeasured, inherited, and substantial risk.

The missed diagnostic opportunity is substantial. In a survey of 512 Latin American physicians, only 36.7% reported ordering Lp(a) testing, and those who did typically requested it only in the setting of premature disease, familial hypercholesterolemia, or recurrent events. Among non-ordering physicians, the primary barriers were test unavailability (57.4%) and cost (33.6%), while only half of respondents correctly identified risk cutoffs^[6]. Similarly, real-world data from diverse geographic regions indicate that physician awareness remains insufficient: a substantial proportion of patients with elevated Lp(a) are identified only after experiencing their first clinical event.

Molecular and Pathophysiological Mechanisms

Apolipoprotein(a) Structure and Genetic Control of Concentration

Lp(a) consists of an LDL-like particle containing apoB-100 covalently linked to apolipoprotein(a) via a single disulfide bond in the kringle IV type 9 domain. Apo(a) evolved from plasminogen through gene duplication. Although it retains ten subtypes of kringle IV, a single copy of kringle V, and an inactive protease-like domain, it lacks the plasminogen activation site. The LPA gene encodes a variable number of kringle IV type 2 repeats, giving rise to more than 40 isoform sizes. Circulating concentration is primarily determined by this repeat number and several single-nucleotide variants, remaining stable throughout life^[7]. Small isoforms are efficiently secreted by hepatocytes. In contrast, large isoforms are retained longer in the endoplasmic reticulum and undergo degradation, explaining the inverse relationship between isoform size and plasma concentration. Assembly with apoB-100 is thought to occur largely on or near the hepatocyte surface. This interaction step is the target of muvalaplin, an oral inhibitor that binds to apo(a) kringle domains to prevent noncovalent docking with apoB.

The clearance mechanism has not yet been fully elucidated. The LDL receptor, and likely other receptors, play a role in the clearance of Lp(a) particles. PCSK9 inhibitors increase LDL receptor expression and availability, lowering Lp(a) levels by 20% to 30%, although some patients exhibit no response^[8]. This modest and variable effect suggests that steady-state concentration is primarily determined by production rather than catabolism. This is also the fundamental reason why hepatic transcript silencing, rather than enhancing clearance, has emerged as a successful therapeutic strategy.

Oxidized Phospholipids as a Pathogenic Cargo

Each Lp(a) particle carries cholesterol; however, its per-particle atherogenicity exceeds that of LDL. A major portion of this excess is attributed to oxidized phospholipids (OxPL), which are covalently bound primarily to the lysine-binding pocket in the kringle IV type 10 domain of apo(a) and transported within the lipid phase of the particle. OxPL activates endothelial and monocyte inflammatory signaling pathways via Toll-like receptor 2 (TLR2) and CD36. It promotes monocyte transmigration and triggers osteogenic differentiation in valvular interstitial cells. Lp(a)-associated autotaxin produces lysophosphatidic acid, which exacerbates valvular calcification. This process provides the plausible mechanistic basis underlying the particularly robust association observed with calcific aortic stenosis.

OxPL-apoB acts pharmacologically as a surrogate marker of Lp(a) biology. In a randomized trial of 591 patients, extended-release niacin reduced OxPL-apoB from 3.5 to 3.1 nM and Lp(a) from 10.9 to 9.3 mg/dL, whereas the ezetimibe/simvastatin combination increased Lp(a) from 11.5 to 14.9 mg/dL (p < 0.01 for each). A companion systematic review of 12 studies identified an average 10.6% increase in Lp(a) levels with statins and a 19.4% increase with low-fat diets, while reporting a 52.0% reduction with Lp(a)-lowering therapies^[9]. This statin-induced elevation is real but small; it does not negate the net clinical benefit of statin therapy and does not constitute a rationale for discontinuing or withholding statins.

The Lp(a) lipidome is not static. In 166 African American adults randomized from an average American diet deriving 16% of energy from saturated fat to a DASH-type diet containing 6% saturated fat, total Lp(a)-OxPL concentrations did not change. Nevertheless, four OxPL subspecies, predominantly ALDOPC, decreased (p = 0.001), and shifts were observed in 87 of 440 identified lipid species. Alterations were more pronounced in participants with an Lp(a) level of 50 mg/dL or higher and varied according to apo(a) isoform size^[10]. Renal disease shifts the lipidome toward a proinflammatory profile. In a study comparing 54 nondiabetic patients with chronic kidney disease to 39 controls, Lp(a)-OxPL was higher (median 2.7 vs 1.2 U/L, p = 0.031), the relative proportion of the POVPC subspecies was 21% vs 16%, and 146 of 437 lipid species—predominantly triacylglycerols and diacylglycerols—were enriched independently of Lp(a) concentration^[11]. Both datasets are small-scale and mechanistic. They suggest that not only particle number, but also particle quality, may vary within an individual patient.

Antifibrinolytic and Prothrombotic Activity

Because apo(a) mimics plasminogen kringle structures, it competes for fibrin and cell-surface binding sites, reducing plasmin generation. It also enhances tissue factor pathway activity and platelet reactivity in experimental systems. These properties form the basis of the hypothesis that antiplatelet therapy may confer disproportionately greater benefit in individuals with elevated Lp(a). This hypothesis is under observational investigation, as discussed below, but has not yet been tested in a dedicated randomized trial.

Inflammation as an Effect Modifier

The risk conferred by Lp(a) may depend on the inflammatory microenvironment. In the placebo arm of the LoDoCo2 trial with colchicine, among patients with stable chronic coronary syndrome, the hazard ratio (HR) for the composite of Lp(a)-associated spontaneous MI, ischemic stroke, or ischemia-driven revascularization was 0.90 (95% CI 0.78 to 1.03) when interleukin-6 was below the median value of 3.2 ng/L. When IL-6 was at or above the median, this ratio was 1.18 (95% CI 1.01 to 1.39; p for interaction = 0.01). No interaction was observed across hsCRP strata (p for interaction = 0.79), and OxPL-apo(a) and OxPL-apoB exhibited the same IL-6-dependent pattern^[12]. This represents a hypothesis-generating subgroup analysis. Nonetheless, it indicates that the IL-6 signaling pathway serves as a mechanistic amplifier of Lp(a)-driven events and represents a potential target for combination therapeutic strategies.

Pharmacological Targets in the Apo(a) Pathway

Existing and investigational therapies act at mechanistically distinct checkpoints. Pelacarsen is a GalNAc-conjugated antisense oligonucleotide cleared by the asialoglycoprotein receptor on hepatocytes. It hybridizes to LPA mRNA to trigger RNase H1-mediated degradation and requires frequent (monthly) subcutaneous dosing. The small interfering RNAs (siRNAs) olpasiran, lepodisiran, and zerlasiran are likewise GalNAc-targeted but are loaded into the RNA-induced silencing complex (RISC), where Argonaute-2 catalytically cleaves successive LPA transcripts. This catalytic mechanism explains the deeper and substantially more prolonged suppression achieved with dosing intervals of three to six months or longer. Muvalaplin, on the other hand, acts directly at the protein level rather than the transcript level, preventing particle assembly.

In contrast, PCSK9 monoclonal antibodies (evolocumab, alirocumab) and the PCSK9 siRNA inclisiran act primarily through receptor-mediated clearance. The cholesteryl ester transfer protein inhibitor obicetrapib lowers Lp(a) through a mechanism that remains incompletely understood. Niacin modestly reduces hepatic apo(a) transcription. Statins, which upregulate LDL receptors but can also increase LPA expression, slightly elevate Lp(a).

Clinical Evidence and Guideline Comparison

Lp(a) and Coronary Artery Calcium: Complementary, Not Redundant, Parameters

Because Lp(a) promotes noncalcified plaque formation, clinicians legitimately question the extent to which a coronary calcium score of zero is reassuring in an individual carrying this genetic variant. A pooled analysis of four prospective US cohorts comprising 11,319 participants free of atherosclerotic cardiovascular disease (ASCVD), with 1,569 events recorded over a median follow-up of 14.8 years, demonstrated that Lp(a) greater than 50 mg/dL (hazard ratio [HR] 1.24; 95% confidence interval [CI] 1.09-1.41) and a coronary artery calcium (CAC) score greater than zero (HR 2.44; 95% CI 2.14-2.77) were independently associated with ASCVD, with no interaction between them (p value for interaction: 0.80). Among participants with a CAC score of zero, event rates were 4.9 and 3.8 per 1,000 person-years in those with and without elevated Lp(a), respectively, corresponding to an absolute difference of 1.1 per 1,000 person-years (HR 1.28; 95% CI 1.01-1.60). In those with CAC greater than zero, the corresponding rates were 21.2 versus 18.2 per 1,000 person-years (an absolute risk increase of 3.0 per 1,000 person-years), and the risk of cardiovascular events was markedly higher in this coronary calcium-positive cohort (HR 3.03; 95% CI 2.52 to 3.64). The combination of CAC of 300 or greater and Lp(a) greater than 50 mg/dL conferred the highest risk (HR 6.12; 95% CI 4.80-7.81)^[13].

The clinical implication of these findings is unambiguous: elevated Lp(a) increases relative risk across all calcium strata. However, in a middle-aged patient with a CAC score of zero, absolute risk over the subsequent 10-year period remains low, and the relative risk increase alone does not mandate pharmacotherapy. Conversely, the detection of an elevated calcium score in an Lp(a) carrier signals an absolute cardiovascular risk profile approaching secondary prevention levels.

Aspirin and Calcific Aortic Valve Disease

The antifibrinolytic biology of apo(a) has rekindled interest in aspirin. In an exploratory analysis of up to 6,598 MESA participants, 23% reported regular aspirin use; over a median follow-up of 8.9 years, 8% developed aortic valve calcification (AVC), and over a median follow-up of 16.7 years, 1% developed severe aortic stenosis. Among participants with an Lp(a) level of 75 mg/dL or greater, regular aspirin use was associated with lower rates of incident AVC (HR 0.42; 95% CI 0.19-0.93) and severe aortic stenosis (HR 0.02; 95% CI 0.001-0.29). When Lp(a) was 50 mg/dL or greater, the hazard ratio for severe aortic stenosis was 0.13 (95% CI 0.04-0.47). No similar association was observed in participants with elevated LDL-C levels^[14].

The confidence intervals are exceptionally wide, the number of incident severe stenosis events is quite limited, and aspirin use was based on self-report rather than randomized allocation. While these data may provide the rationale for a randomized clinical trial focused on preventing valvular pathology, they fall far short of supporting routine aspirin use for valvular protection.

PCSK9 Inhibition as the Best Available Evidence-Based Option

To date, no randomized trial has proven that directly lowering Lp(a) reduces cardiovascular events. The closest available evidence derives from PCSK9 clinical outcome trials. In FOURIER with evolocumab and ODYSSEY OUTCOMES with alirocumab, baseline Lp(a) levels predicted events independently of LDL-C. The modest Lp(a) reduction achieved with treatment was associated with fewer cardiovascular events; in ODYSSEY OUTCOMES, this association remained significant after adjustment for demographic variables, baseline and on-treatment LDL-C levels, and clinical covariates. Analyses evaluating PCSK9 trial pools emphasize that in the FOURIER cohort, the most pronounced cardiovascular event reduction occurred in the patient subgroup in whom both LDL-C and Lp(a) levels were simultaneously lowered^[8]. Because these analyses represent observational data embedded within randomized trials, the Lp(a)-specific contribution cannot be definitively disentangled from LDL lowering. Nevertheless, these data support the prioritized and early use of PCSK9 inhibition in secondary prevention patients with elevated Lp(a) levels.

CETP Inhibition: Obicetrapib

Obicetrapib at 10 mg daily was evaluated in a pooled analysis of 12-week trials comprising 2,356 patients with heterozygous familial hypercholesterolemia or ASCVD, of whom 91% were receiving statin therapy. Compared with a median baseline level of 42.9 nmol/L, the drug produced placebo-adjusted reductions in LDL-C of 37.0% (35 mg/dL), apoB of 21.3%, and Lp(a) of 37.3% (14.9 nmol/L). In patients with baseline Lp(a) levels between 50 and less than 150 nmol/L, the Lp(a) reduction was 43.3% (36.3 nmol/L). In those with baseline levels of 150 nmol/L or higher, the percentage reduction was more modest, but the absolute reduction was similar at 32.3 nmol/L^[15]. This consistent absolute reduction of approximately 30 to 35 nmol/L may offer the most clinically meaningful contribution for mildly elevated phenotypes that are unlikely to qualify for RNA-targeted therapies. Whether this effect translates into event reduction beyond the benefits achieved through LDL-C and apoB lowering remains unknown.

RNA-Targeted Therapies: Efficacy Signals

In Phase 1 and 2 programs, profound reductions of up to 95% to 100% relative to placebo have been observed with siRNA agents such as olpasiran, zerlasiran, and lepodisiran, alongside Lp(a) reductions of approximately 80% with pelacarsen and up to 85% with oral muvalaplin^[4]. Next-generation siRNAs, particularly zerlasiran and lepodisiran, have been comprehensively evaluated with regard to their safety and efficacy profiles^[16].

First-in-human data clearly illustrate the remarkable durability of effect achieved with these platforms. In a randomized, double-blind, placebo-controlled phase 1 trial of Kylo-11, a noncanonical, long-acting siRNA, 70 of 71 randomized participants with a median age of 27.5 years received a single dose of study drug or placebo and were followed for a median of 337 days. At week 48, prespecified secondary pharmacodynamic endpoints showed that median Lp(a) reductions ranged from 53% (71 nmol/L) in the 9-mg cohort to 97% (129 nmol/L) in the 600-mg cohort. In the 225-mg cohort with baseline Lp(a) levels greater than 200 nmol/L, the median reduction reached 96% (208 nmol/L). Across the 24-week safety assessment window, 53% of patients (37/70) experienced mild (Grade 1-2) general adverse events; no serious adverse events, injection site reactions, or adverse effects deemed directly related to the drug were reported. Observed Grade 3 laboratory abnormalities were confined to transient hypertriglyceridemia and creatine phosphokinase elevations, which were evaluated as unrelated to the study drug^[17]. Given that the studied cohort was small and composed of young individuals, these results currently substantiate pharmacological success rather than clinical benefit.

Guideline Approaches

Major professional societies currently recognize Lp(a) as an independent risk factor. Guidelines recommend universal screening at least once in a lifetime for adults, or at a minimum, targeted screening of high-risk populations^[18]. Guideline strategies differ in scope and diagnostic thresholds. The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) recommend measurement at least once in every adult, defining values above approximately 50 mg/dL (roughly 105 to 125 nmol/L) as a risk-enhancing factor, while designating 30 to 50 mg/dL as a gray zone. The 2018 ACC/AHA cholesterol guideline identifies Lp(a) levels of 50 mg/dL or 125 nmol/L and higher as a risk-enhancing factor in statin decision-making. The Canadian Cardiovascular Society recommends once-in-a-lifetime testing with a threshold of 50 mg/dL or 100 nmol/L. The National Lipid Association has moved toward a universal screening approach. Where threshold values differ, this divergence reflects assay heterogeneity and cohort calibrations rather than a discrete biological cut-off, as cardiovascular risk increases continuously in tandem with Lp(a) concentration.

Practical Implications and Safety Profile

Who Should Be Tested and How Should Results Be Interpreted?

Every adult should have their Lp(a) level measured at least once. Testing is prioritized in the following patient groups:

• patients with premature atherosclerotic cardiovascular disease (ASCVD) (men younger than 55 years, women younger than 65 years)
• patients experiencing recurrent events despite achieving target LDL-C levels
• those with familial hypercholesterolemia or patients developing calcific aortic stenosis at a younger age than expected
• individuals with a family history of premature ASCVD or elevated Lp(a)
• patients with borderline or intermediate 10-year risk in whom the test result could alter clinical management

Cascade screening should be performed in first-degree relatives of an index patient found to have elevated Lp(a) levels^[19]. Because plasma concentrations are largely established in early childhood, testing children with a strong family history is a reasonable approach.

An assay calibrated against WHO/IFCC reference materials and reported in nmol/L should be requested. Such assays are less sensitive to isoform size compared with mass-based measurements. Conversion of mg/dL to nmol/L using a fixed conversion factor between approximately 2.0 and 2.5 is merely a rough estimate and has the lowest reliability at the extremes of isoform size. In clinical practice, the following interpretive thresholds should be used:

• less than 75 nmol/L (approximately 30 mg/dL): low risk contribution
• 75 to 125 nmol/L: intermediate risk
• 125 nmol/L or higher (approximately 50 mg/dL): risk-enhancing factor
• greater than 430 nmol/L (approximately 180 mg/dL): risk equivalent to heterozygous familial hypercholesterolemia

A single measurement is sufficient in most patients. However, measurement should be repeated following clinical conditions that elevate Lp(a) levels—such as CKD (chronic kidney disease), nephrotic syndrome, hypothyroidism, menopause, or acute inflammation—and prior to enrollment in a clinical trial. Laboratory-reported LDL-C also includes Lp(a)-cholesterol, which accounts for approximately 30% to 45% of Lp(a) mass. Therefore, an apparent lack of response to statins in patients with very high Lp(a) levels may partially reflect this contribution. ApoB should also be measured concurrently.

Phenotype-Based Treatment Algorithm

Primary prevention, intermediate risk, Lp(a) 125 nmol/L or higher. Elevated Lp(a) should be treated as a risk-enhancing factor, and a coronary artery calcium (CAC) score should be obtained to clarify absolute risk. Low-dose aspirin may be considered in selected patients with low bleeding risk^[19]. If the CAC score is zero and no other high-risk features are present, focus should remain on lifestyle modifications and risk factor control, with consideration of repeat screening in approximately five years. If the CAC score is between 1 and 99, at least moderate-intensity statin therapy should be initiated. If the CAC score is 100 or higher, or at or above the 75th percentile for age and sex, secondary prevention-intensity therapy should be implemented with an LDL-C target below 70 mg/dL. If the CAC score is 300 or higher, a target below 55 mg/dL is reasonable.

Secondary prevention with Lp(a) 125 nmol/L or higher. High-intensity statin therapy should be initiated, ezetimibe added early, and PCSK9 inhibition pursued if LDL-C remains above 55 mg/dL. In this patient population, PCSK9 inhibition is preferred over further statin dose titration or other adjunctive therapies, as it also confers a modest reduction in Lp(a).

Familial hypercholesterolemia with concomitant high Lp(a). In this cohort, Lp(a) and LDL-C risks are cumulative; therefore, the most aggressive tolerated LDL-C-lowering strategy should be implemented, and relatives should be screened for both traits.

Aortic valve surveillance. There is no evidence-based defined imaging interval for asymptomatic carriers. Echocardiography is indicated in any patient with a murmur detected on physical examination. While there is no guideline consensus on routine valvular screening in asymptomatic individuals, a baseline echocardiographic evaluation may be considered as an expert clinical approach in selected older individuals with marked Lp(a) elevation (>175 nmol/L). If aortic sclerosis is present, standard surveillance intervals should be followed.

Dosing of Available Agents

The established regimens outlined below should be utilized and confirmed against locally approved product labeling:

• High-intensity statin: atorvastatin 40 to 80 mg daily or rosuvastatin 20 to 40 mg daily. In patients of East Asian ancestry or with an eGFR below 30 mL/min/1.73 m2, rosuvastatin 5 to 10 mg daily should be used.
• Ezetimibe: 10 mg daily.
• Evolocumab: 140 mg subcutaneously every two weeks or 420 mg monthly.
• Alirocumab: 75 mg every two weeks (titratable to 150 mg every two weeks) or 300 mg every four weeks.
• Inclisiran: 284 mg subcutaneously on day 0 and month 3, then every six months thereafter.
• Bempedoic acid: 180 mg daily in patients with statin intolerance. Uric acid levels should be monitored, as it may precipitate gout flares.
• Low-dose aspirin when preferred: 75 to 100 mg daily.

Extended-release niacin should not be used to lower Lp(a) levels. Clinical outcome trials with niacin failed to demonstrate a reduction in cardiovascular events and instead revealed an excess of adverse effects, including new-onset diabetes, infection, and bleeding. Hormone therapy should likewise not be considered an Lp(a) strategy.

Safety Monitoring

• Check a fasting or nonfasting lipid panel including apoB 4 to 12 weeks after initiating or titrating any therapy, and every 6 to 12 months thereafter.
• Measure baseline ALT prior to statin therapy and repeat only when clinically indicated. Discontinue therapy if ALT persistently exceeds three times the upper limit of normal.
• Measure CK only in the presence of symptoms. Discontinue the statin if CK exceeds ten times the upper limit of normal or if symptoms are intolerable; then rechallenge with a lower dose or an alternative agent.
• Be vigilant for statin interactions with potent CYP3A4 inhibitors—such as clarithromycin, itraconazole, ritonavir-boosted regimens, and large quantities of grapefruit juice—when using simvastatin or atorvastatin. Concomitant use of cyclosporine, gemfibrozil, and ticagrelor with high-dose simvastatin also necessitates dose restrictions or agent substitution.
• Monitor for injection-site reactions and nasopharyngitis with PCSK9 antibodies; neither condition requires laboratory surveillance.
• With aspirin use, perform a bleeding risk assessment at initiation, consider adding proton pump inhibitor gastroprotection in patients with a history of peptic ulcer disease, and review therapy annually.

Lipoprotein Apheresis

Apheresis selectively removes apoB-containing lipoproteins, including Lp(a). It has demonstrated efficacy in secondary prevention patients with elevated Lp(a) who fail to achieve LDL-C goals. However, its use is limited by the availability of specialized centers^[20]. The optimal candidate for this therapy is a patient with an Lp(a) level above approximately 60 mg/dL (roughly 120 to 150 nmol/L) and documented progressive ASCVD (recurrent events or angiographic progression) despite maximally tolerated LDL-lowering therapy that includes a PCSK9 inhibitor. The German reimbursement system has officially recognized this phenotype. Apheresis is performed weekly or biweekly, and each session acutely lowers Lp(a) levels by approximately 60% to 75%. Because plasma concentrations rebound between sessions, the time-averaged reduction is substantially lower (approximately 25% to 35%). Patients with stable disease, those with an indication solely for primary prevention, or those with inadequate vascular access are unlikely to derive a benefit that justifies the procedural burden.

Future Perspectives and Open Questions

Everything hinges on the phase 3 outcomes trials testing whether pharmacological Lp(a) lowering translates into a reduction in clinical events. These programs include Lp(a)HORIZON evaluating pelacarsen, OCEAN(a)-Outcomes evaluating olpasiran, and ACCLAIM-Lp(a) evaluating lepodisiran^[4]. Muvalaplin and other RNA-targeted therapeutics follow in close succession, with all of these therapies achieving reductions of up to 99% in early-phase trials^[1].

Several trial design elements will dictate how the resulting findings translate into clinical practice.

• Magnitude of absolute reduction required. Mendelian randomization estimates suggest that the reduction in clinical events is proportional to the absolute drop in Lp(a) concentration rather than the percent change. Consequently, patients with baseline values around 125 nmol/L may derive limited benefit even with near-complete suppression.
• Time course of benefit. Whether a four- to five-year clinical trial can capture the clinical dividends of reversing a lifelong exposure remains uncertain.
• Enrolled populations. These trials predominantly enroll secondary prevention patients with Lp(a) levels of approximately 175 to 200 nmol/L or higher. Generalizing findings to primary prevention, women, and Black individuals who have higher population-level Lp(a) distributions will require caution.

Aortic stenosis represents an entirely distinct therapeutic frontier. To date, no outcome trial has been adequately powered for valvular endpoints, and the exploratory signal associated with aspirin described above awaits randomized validation. Whether early silencing slows progression from aortic sclerosis to hemodynamically significant stenosis may prove just as critical as the coronary question. Ultra-long-acting agents such as Kylo-11 introduce a pharmacovigilance dilemma that current clinical trials cannot resolve. Near-complete, continuous suppression of a protein with no known essential physiologic function in humans appears well tolerated for up to 48 weeks; however, long-term safety spanning decades remains uncharted.

Particle quality introduces an additional layer of complexity. Diet, chronic kidney disease (CKD), and inflammation alter the OxPL cargo and lipidome of Lp(a), and IL-6 appears to modify the event risk conferred by the particle. It is plausible that OxPL-apo(a) or an adjunctive inflammatory biomarker could refine patient selection more precisely than concentration alone. Combination strategies coupling Lp(a) silencing with IL-6 pathway inhibition represent a logical next step, though they remain speculative.

Clinical implementation remains the most urgent gap to bridge. Assay standardization, harmonized reporting in nmol/L, reimbursement coverage for one-time testing, and physician education would enable the identification of millions of carriers today, well before a new drug is approved. Until clinical outcome data become available, the most appropriate stance is disciplined management rather than therapeutic nihilism. Measure Lp(a) once, use it to calibrate the intensity of LDL-C and global risk factor control, perform cascade family screening, and reserve apheresis and investigational trial enrollment exclusively for the highest-risk phenotypes.

References

1. Bene-Alhasan Y, Nambi V, Abushamat LA, Ballantyne CM. Targeting Lipoprotein(a): A New Era in Cardiovascular Disease Prevention. Methodist Debakey Cardiovasc J. 2026;22(4):28-39. doi:10.14797/mdcvj.1836. PubMed
2. Crea F. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: an emerging therapeutic target. Eur Heart J. 2022;43(39):3815-3818. doi:10.1093/eurheartj/ehac553. PubMed
3. Nurmohamed NS, Moriarty PM, Stroes ESG. Considerations for routinely testing for high Lp(a). Curr Opin Lipidol. 2022;33(3):213-218. doi:10.1097/MOL.0000000000000828. PubMed
4. González JPM. Lipoprotein(a): Cardiovascular Risk and Emerging Targeted Therapies. Am J Cardiovasc Drugs. 2026. Online ahead of print. doi:10.1007/s40256-026-00825-5. PubMed
5. Bobrowska B, Dziewierz A, Domienik-Karłowicz J, Zasada W, Rajtar-Salwa R, Rulkiewicz A, et al. Distribution of lipoprotein(a) and its association with atherosclerotic cardiovascular disease in a large real-world Polish cohort. J Clin Lipidol. 2026;20(9):1998-2007. doi:10.1016/j.jacl.2026.07.026. PubMed
6. Cruz-Bautista I, Flores-Jurado Y, Barajas-Martínez A, Castillo-Núñez Y, Elías-López D, Ramos-Guifarro MA, et al. Lp(a) Testing in Latin America: Low Awareness and Clinicalpractice Among Medical Society Physicians Highlight a Missed Opportunity in Cardiovascular Prevention. BMC Cardiovasc Disord. 2025;26(1):60. doi:10.1186/s12872-025-05461-6. PubMed
7. Ferrandino M, Cerrato Y, Iannuzzo G, Calcaterra IL, Di Minno MND, Fortunato G, et al. Genetic Influence on LDL-Cholesterol Levels: Role of Polygenic Risk Scores and Lp(a) Beyond Monogenic Hypercholesterolemia. Genes (Basel). 2026;17(6):721. doi:10.3390/genes17060721. PubMed
8. Julius U, Tselmin S, Schatz U, Fischer S, Bornstein SR. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors. Clin Res Cardiol Suppl. 2019;14(Suppl 1):45-50. doi:10.1007/s11789-019-00099-z. PubMed
9. Yeang C, Hung MY, Byun YS, Clopton P, Yang X, Witztum JL, et al. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). J Clin Lipidol. 2016;10(3):594-603. doi:10.1016/j.jacl.2016.01.005. PubMed
10. Myagmarsuren M, Law HG, Zhang W, Bang H, Bishop LM, Shen T, et al. Lipoprotein(a) lipidome and diet: responses to reducing saturated fat intake in African Americans in a randomized trial. J Lipid Res. 2026;67(5):101032. doi:10.1016/j.jlr.2026.101032. PubMed
11. Khan MA, Myagmarsuren M, Zhang W, Law HG, Sanchez M, Roshanravan B, et al. Lipoprotein(a) lipidome and chronic kidney disease: Enrichment in triacylglycerols and diacylglycerols. J Clin Lipidol. 2026;20(7):1417-1429. doi:10.1016/j.jacl.2026.05.225. PubMed
12. Mohammadnia N, van Broekhoven A, Bax WA, Eikelboom JW, Mosterd A, Fiolet ATL, et al. Interleukin-6 modifies Lipoprotein(a) and oxidized phospholipids associated cardiovascular disease risk in a secondary prevention cohort. Atherosclerosis. 2025;405:119211. doi:10.1016/j.atherosclerosis.2025.119211. PubMed
13. Bhatia HS, Fan Y, Dharmavaram G, Razavi AC, Tsai MY, Ramsis M, et al. Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study. J Am Coll Cardiol. 2026;87(20):2864-2872. doi:10.1016/j.jacc.2026.02.5067. PubMed
14. Razavi AC, Bhatia HS, Marrero N, Dzaye O, Post WS, Nasir K, et al. Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis. Eur Heart J. 2026;47(34):4792-4801. doi:10.1093/eurheartj/ehag018. PubMed
15. Nicholls SJ, Nelson AJ, Ray KK, Ditmarsch M, Kling D, Hsieh A, et al. Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials. Eur Heart J. 2026;47(26):3404-3414. doi:10.1093/eurheartj/ehag399. PubMed
16. Baragetti A, Norata GD. The new generation of small interfering RNAs directed against apoprotein(a): focus on the safety and efficacy of zerlasiran and lepodisiran. Cardiovasc Res. 2025;121(13):1969-1971. doi:10.1093/cvr/cvaf153. PubMed
17. Sarraju A, Du X, Zhou L, Laffin LJ, Wolski K, Gu Y, et al. Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. Lancet. 2026;408(10558):899-909. doi:10.1016/S0140-6736(26)01484-4. PubMed
18. Crain N. Lipoprotein(a) screening: Balancing benefits and challenges in clinical decision-making. JAAPA. 2026;39(6):16-21. doi:10.1097/01.JAA.0000000000000361. PubMed
19. Bess C, Mehta A, Joshi PH. All we need to know about lipoprotein(a). Prog Cardiovasc Dis. 2024;84:27-33. doi:10.1016/j.pcad.2024.05.007. PubMed
20. Sbrana F, Dal Pino B, Schettler VJJ, Muso E, Harada-Shiba M, Di Mola M, et al. Lipoprotein apheresis in the era of new lipid-lowering therapies. Eur Heart J. 2026. Online ahead of print. doi:10.1093/eurheartj/ehag328. PubMed

Share this article

LinkedIn X Facebook WhatsApp Copy Link